Cargando…

Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)

AIM: Real-life studies are needed to confirm the clinical relevance of findings from randomised controlled trials (RCTs). This study aimed to assess the effectiveness and tolerability of vildagliptin add-on vs. other oral antihyperglycaemic drugs (OADs) added to OAD monotherapy in a real-life settin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathieu, C, Barnett, A H, Brath, H, Conget, I, de Castro, J J, Göke, R, Márquez Rodriguez, E, Nilsson, P M, Pagkalos, E, Penfornis, A, Schaper, NC, Wangnoo, S K, Kothny, W, Bader, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2013
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231206/ https://www.ncbi.nlm.nih.gov/pubmed/23961850 http://dx.doi.org/10.1111/ijcp.12252

Ejemplares similares

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
por: Schweizer, Anja, et al.
Publicado: (2013)

Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany
por: Göke, Rüdiger, et al.
Publicado: (2014)

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
por: Lukashevich, Valentina, et al.
Publicado: (2013)

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
por: Kothny, Wolfgang, et al.
Publicado: (2015)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
por: Schweizer, Anja, et al.
Publicado: (2011)

Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study
por: Williams, Rachael, et al.
Publicado: (2019)

Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies
por: Kozlovski, Plamen, et al.
Publicado: (2017)

Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study
por: Saab, Charles, et al.
Publicado: (2015)

Research: Treatment Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard-of-care metformin monotherapy—the VERIFY trial: a randomized double-blind trial
por: Del Prato, S, et al.
Publicado: (2014)

Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Odawara, Masato, et al.
Publicado: (2015)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data
por: Kamenov, Zdravko
Publicado: (2014)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study
por: Williams, Rachael, et al.
Publicado: (2019)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
por: Mathieu, Chantal, et al.
Publicado: (2008)

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)
por: Polyakova, E. B., et al.
Publicado: (2022)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury
por: Sherif, Iman O., et al.
Publicado: (2020)

A case of vildagliptin-induced interstitial pneumonia
por: Kuse, Naoyuki, et al.
Publicado: (2016)

Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis
por: Brath, Helmut, et al.
Publicado: (2017)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes
por: Blüher, Matthias, et al.
Publicado: (2014)

Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy
por: Brath, H, et al.
Publicado: (2016)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

Vildagliptin/metformin: Lactic acidosis and hypoglycaemia: case report
Publicado: (2022)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
por: Takeshita, Yumie, et al.
Publicado: (2015)

Second WSES convention, WJES impact factor, and emergency surgery worldwide
por: Catena, Fausto, et al.
Publicado: (2013)

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
por: Foley, James E, et al.
Publicado: (2010)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
por: Dejager, Sylvie, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kl9ip4h1dc5g5fk9m9lpr0msvr